During a live event, Ahmad Tarhini, MD, PhD, and participants discussed how to use combination immunotherapy in patients with ...

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...

Mitochondrial mutation MT haplogroup T strongly predicts poor response to immune checkpoint inhibitors in metastatic melanoma ...

Zeynep Eroglu, MD, discusses the use of a triplet regimen vs standard doublet therapy for the treatment of brain metastases in patients with melanoma.

Patients with metastatic melanoma in mitochondrial haplogroup T are significantly less likely to respond to immunotherapy.

Results from a new study help resolve the decade-long mystery of why many patients with the deadliest form of skin cancer do not respond to the latest cancer treatments.